Novo Nordisk (NVO.US) saw its stock price rise over 7% on Friday, as its new GLP-1 drug Wegovy for treating obesity achieved positive results in its initial launch in the United States.
Analysts reported that Novo Nordisk's new weight loss drug had approximately 4,290 prescriptions written in its first week on the market, most of which were for the initial dosage; in contrast, Eli Lilly's (LLY.US) weight loss drug Zepbound had about 1,900 prescriptions in its first week. The drug was approved at the end of December last year and officially launched on January 5

Novo Nordisk's stock price rose by more than 7% as its new weight loss drug Wegovy performed well in its first week of sales in the United States, with approximately 4,290 prescriptions written, far exceeding Eli Lilly's Zepbound drug's 1,900 prescriptions. Wegovy was approved at the end of December last year and officially launched on January 5

諾和諾德股價漲 7% 其減肥藥 Wegovy 上市首周銷售正面